Anzeige
Mehr »
Samstag, 28.02.2026 - Börsentäglich über 12.000 News
Wegweisende News: NurExone - Pionier der regenerativen neuronalen Medizin!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
15:48Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting1
12:26Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?2
11:013 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade2
10:05Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?5
05:59FDA Grants Accelerated Approval To Ascendis Pharma's YUVIWEL For Achondroplasia In Children10
05:59Aardvark Therapeutics Pauses Phase 3 Trial Of ARD-101 In Prader-Willi Syndrome; Stock Plunges9
05:29Prothena To Buy Back Up To $100 Mln Of Shares1
04:36Ascendis Pharma wins FDA approval for navepegritide for achondroplasia1
04:30FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up376WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for...
► Artikel lesen
02:18Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange4
02:00BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)417Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the...
► Artikel lesen
00:01Ascendis Pharma: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older144The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric...
► Artikel lesen
FrHarrow Health Q4 2025 Earnings Preview3
FrDisc Medicine undergoes restructuring plan; slashes 20% of workforce4
FrTectonic Therapeutic, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
FrAnalyst Bullish on Cogent (COGT) Amid Expected Drug Approval2
FrCiti, Stifel Bullish on Olema (OLMA) Despite COO Departure3
FrP/E Ratio Insights for Gilead Sciences4
FrWhat Analysts Are Saying About CG Oncology Stock1
FrAdaptive Biotechnologies Corp - S-8, Securities to be offered to employees in employee benefit plans8
Weiter >>